FTC Clinical Study Standards and Intraosseous Treatment
In the last post, I reviewed some of the issues and lessons from the Shapiro, et al. papers, as they related to doing higher level clinical studies with BMC. However, even their study didn’t meet the newly minted standard set by the FTC in the court Order issued last October. In that court Order, the...
Read More
FTC Clinical Study Standards and Placebo Control
In the previous post, I had completed my review of the clinical findings published in a second paper by Shapiro, et al. confirming the utility of injecting saline into one OA-afflicted knee and BMC into the other OA-afflicted knee when treating patients with bilateral knee OA. Certainly, their approach is a novel way for treating...
Read More
FTC Level 1 Clinical Study Standards and BMC
In the previous post, I had left you hanging on the follow-up publication by Shapiro, et al. that was published last year (2018). I wanted to review both papers in light of the recently established precedent obtained by the FTC in a Federal court Order issued last October, in which the FTC laid out the...
Read More
FTC Clinical Study Standards BMC
In the previous post, I had focused on the implications of the FTC Order issued last October as it pertains to the type of clinical studies required if a clinic or health care provider wanted to make health-related claims about the therapies they provide and to advertise these claims. The FTC obtained Federal court endorsement...
Read More
FTC and umbilical cord-derived stem cells
The recent FTC actions against a physician who practiced miraculous regenerative medicine suggest a tightening of the allowed actions and activities of the field with respect to making claims and advertising, which clinics use to differentiate themselves from the group down the street. However, the recent FTC court action shows the perils going forward of...
Read More
False claims about amniotic stem cells
Over the previous four posts, I have reviewed the FTC’s legal actions taken against a physician who advertised what I call miraculous regenerative medicine on the Internet, in which amazing claims of therapeutic benefit were announced for treating virtually any pathologic condition, including ALS, MS, COPD, chronic kidney disease, autism, etc. I provided examples from the...
Read More
FTC Actions Against False Claims
In the previous three posts (Part One, Part Two, Part Three), I have been reviewing aspects of the FTC’s recent court case against Dr. Henderson, who was charged by the FTC with false advertising by making clinically-unsupported claims about the therapeutic power of amniotic stem cells. Dr. Henderson acknowledged engaging in false advertising and making...
Read More
FTC Against Dr. Henderson
For the past two posts (Part One and Part Two), I have covered the case of Dr. Bryn Henderson, who was taken to court in October by the Federal Trade Commission (FTC) over his completely unsupported and deceptive claims concerning the miraculous therapeutic benefit of amniotic stem cells to treat every aliment known to mankind...
Read More
FTC Against False Claims
In the last post, I had introduced the sins of Dr. Henderson, who was cited by the FTC for advertising MRM—miraculous regenerative medicine. Needless to say, the FTC took exception to the outlandish and false claims Dr. Henderson made on his now-inaccessible website(s), so I will perform a public service by sharing with you my...
Read More